What changed in our tablet and provider coverage this week
A short update on recent tablet and provider comparison improvements and what readers can now check more easily.
27 May 2026 · 1 min readNews and updates
Shorter, timely site updates and comparison-coverage notes that help readers understand what is new and what can now be checked more clearly.
Semaglutide and heart-risk guidance: why the 2026 NICE update matters
NICE’s 2026 semaglutide recommendation is not just a weight-loss story. It shows why indication, eligibility and context matter.
26 May 2026 · 2 min read
Generic semaglutide in Canada: what it does and does not mean for the UK
Canada has approved generic semaglutide injections, but that does not mean a generic Wegovy route or new UK provider access is here. This is what the change actually…
23 May 2026 · 3 min read
Retatrutide Weight Loss Trial Results: What the New Eli Lilly Data Could Mean in the UK
Retatrutide delivered strong late-stage weight loss results, but it is not approved for routine UK prescribing. Here is what the new Eli Lilly data means and what to…
23 May 2026 · 4 min read This week’s comparison update: where the parent site now sends Wegovy, Mounjaro and tablet questions
An update on how the parent site now routes broader questions into the right specialist comparison without losing the educational overview.
20 May 2026 · 2 min read
What changed in our provider checks this week
A quick reader-facing update on what is clearer in the provider comparison guide and how to use it more carefully.
13 May 2026 · 2 min read This week’s comparison update: tablet and capsule routes are easier to compare
A short update on how the tablet and capsule section now helps readers compare routes more clearly and move between the right pages more easily.
1 May 2026 · 3 min read